You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (4) |
Back to Search
COMPARATIVE SAFETY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
- At: AbuDhabi (United Arab Emirates) (2019)
- Type: Poster
- Poster code: POS-HPS-058
- By: KAO, Chi-Lan (cathay general hospital, pharmacy, China Taiwan)
- Co-author(s): Chi-Lan Kao: pharmacy, cathay general hospital, taipei, China Taiwan;Pharmacists, Association, taipei, China Taiwan
Tsai-Ling Chiang: pharmacy, cathay general hospital, taipei, China Taiwan;Pharmacists, Association, taipei, China Taiwan
Ting-Ching Wu: pharmacy, cathay general hospital, taipei, China Taiwan;Pharmacists, Association, taipei, China Taiwan
Wan-Tsui Huang: pharmacy, cathay general hospital, taipei, China Taiwan;Pharmacists, Association, taipei, China Taiwan;School of Pharmacy, Taipei Medical University, taipei, China Taiwan - Abstract:
Background
Safety of different direct oral anticoagulants (DOACs) (dabigatran, rivaroxaban, edoxaban and apixaban) in patients with non-valvular atrial fibrillation (NVAF) has not been evaluated in clinical practice..
Methods
This was a retrospective cohort study. We included patients with NVAF who initiated any of DOACs in the Cathay General.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026